Opportunities and challenges in phenotypic drug discovery: an industry perspective (Q39420418)

11 September 2017

1 reference

title

Opportunities and challenges in phenotypic drug discovery: an industry perspective (English)

1 reference

11 September 2017

1 reference

John G Moffat

1 reference

11 September 2017

Fabien Vincent

1 reference

11 September 2017

Jonathan A Lee

1 reference

11 September 2017

Jörg Eder

1 reference

11 September 2017

Marco Prunotto

1 reference

11 September 2017

language of work or name

1 reference

7 July 2017

1 reference

Nature Reviews Drug Discovery

11 September 2017

published in

1 reference

11 September 2017

1 reference

11 September 2017

1 reference

11 September 2017

page(s)

531-543

1 reference

How were new medicines discovered?

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Induced pluripotent stem cell technology: a decade of progress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Cornerstones of CRISPR-Cas in drug discovery and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

The discovery of first-in-class drugs: origins and evolution.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Phenotypic screening in cancer drug discovery - past, present and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Developing predictive assays: the phenotypic screening "rule of 3".

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

The phenotypic screening pendulum swings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Phenotypic screening: the future of antibody discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Modern approaches in the search for new lead antiparasitic compounds from higher plants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

PCSK9: Regulation and Target for Drug Development for Dyslipidemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

The discovery of medicines for rare diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Power of rare diseases: found in translation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Screening out irrelevant cell-based models of disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Comparative genomics as a tool to understand evolution and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Defining Glomerular Disease in Mechanistic Terms: Implementing an Integrative Biology Approach in Nephrology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

JAK inhibition in the treatment of diabetic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

A disease model of diabetic nephropathy in a glomerulus-on-a-chip microdevice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Neuropathological assessment and validation of mouse models for Alzheimer's disease: applying NIA-AA guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Pathway reporter genes define molecular phenotypes of human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Highly sensitive amplicon-based transcript quantification by semiconductor sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Data mining reveals a network of early-response genes as a consensus signature of drug-induced in vitro and in vivo toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

White-to-brown metabolic conversion of human adipocytes by JAK inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Microarrays and toxicology: the advent of toxicogenomics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Intersection of toxicogenomics and high throughput screening in the Tox21 program: an NIEHS perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Molecular Phenotyping Combines Molecular Information, Biological Relevance, and Patient Data to Improve Productivity of Early Drug Discovery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Treatment of obesity with celastrol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

31 March 2020

The South Asian genome.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Genomics takes hold in Asia. Interview by David Cyranoski

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Three-dimensional culture systems in cancer research: Focus on tumor spheroid model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Organs-on-chips at the frontiers of drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Multiparametric Analysis of Oncology Drug Screening with Aqueous Two-Phase Tumor Spheroids.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Spheroid-based drug screen: considerations and practical approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Microtissues in Cardiovascular Medicine: Regenerative Potential Based on a 3D Microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Spherical cancer models in tumor biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Production of 3-D Airway Organoids From Primary Human Airway Basal Cells and Their Use in High-Throughput Screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

iPS cell derived neuronal cells for drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Pluripotent stem cells in disease modelling and drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Preclinical target validation using patient-derived cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Ivacaftor potentiation of multiple CFTR channels with gating mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

A comprehensive transcriptional portrait of human cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Advances and challenges in hereditary cancer pharmacogenetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Accelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Prospective derivation of a living organoid biobank of colorectal cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Characterization of chemical libraries for luciferase inhibitory activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

The value of translational biomarkers to phenotypic assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Phenotypic screening, take two

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Drug discovery: a historical perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

How many drug targets are there?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Drug development: Raise standards for preclinical cancer research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Believe it or not: how much can we rely on published data on potential drug targets?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Clinical development success rates for investigational drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Overview of FTY720 clinical pharmacokinetics and pharmacology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

The promise and peril of chemical probes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Evidence-Based and Quantitative Prioritization of Tool Compounds in Phenotypic Drug Discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Applications of chemogenomic library screening in drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

A comprehensive map of molecular drug targets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Dark chemical matter as a promising starting point for drug lead discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Biology-oriented synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Natural Products as Sources of New Drugs from 1981 to 2014.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

The re-emergence of natural products for drug discovery in the genomics era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Diversity-oriented synthesis yields novel multistage antimalarial inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Transcriptional Characterization of Compounds: Lessons Learned from the Public LINCS Data.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Compound signature detection on LINCS L1000 big data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Chemoproteomic profiling and discovery of protein electrophiles in human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Proteome-wide covalent ligand discovery in native biological systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Ligand and Target Discovery by Fragment-Based Screening in Human Cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Spiroindolones, a potent compound class for the treatment of malaria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Multidimensional drug profiling by automated microscopy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

High-content phenotypic profiling of drug response signatures across distinct cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Nobel lecture in physiology or medicine--1988. Drugs from emasculated hormones: the principle of syntopic antagonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Can animal models of disease reliably inform human studies?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

In vitro cardiotoxicity assessment of environmental chemicals using an organotypic human induced pluripotent stem cell-derived model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Human induced pluripotent stem cell-derived hepatocytes for toxicology testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Target (In)Validation: A Critical, Sometimes Unheralded, Role of Modern Medicinal Chemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Identification of protein binding partners of small molecules using label-free methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Target identification by image analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Identifying compound efficacy targets in phenotypic drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Functional Genomics in Pharmaceutical Drug Discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

The impact of CRISPR-Cas9 on target identification and validation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Target identification for biologically active small molecules using chemical biology approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Functional genomics to uncover drug mechanism of action.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Phenotypic Assessment and the Discovery of Topiramate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Topiramate in migraine prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Brivaracetam: a rational drug discovery success story

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Nintedanib: from discovery to the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.111

Robotic production of cancer cell spheroids with an aqueous two-phase system for drug testing

31 March 2020

1 reference

12 December 2020

In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform

1 reference

12 December 2020

Past, present, and future of high content screening and the field of cellomics

1 reference

12 December 2020

Involvement of patient organisations in research and development of orphan drugs for rare diseases in europe

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2017.111

1 reference

Dimensions Publication ID

11 September 2017

1090372052

0 references

1 reference